Oragenics (OGEN) announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio. The partnership aims to utilize advanced AI modeling to identify optimal receptor binding profiles for novel compounds acquired by Oragenics in 2023. Receptor.AI will apply its proprietary computational models to analyze Oragenics’ molecule structures to inform laboratory testing strategy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN: